<?xml version="1.0" encoding="UTF-8"?>
<ref id="B19-viruses-09-00147">
 <label>19.</label>
 <element-citation publication-type="confproc">
  <person-group person-group-type="author">
   <name>
    <surname>Grimley</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Maron</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Prasad</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Jacobsohn</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Young</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Chittick</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Brundage</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Mommeja-Marin</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>In Preliminary results from the advise study evaluating brincidofovir (bcv, cmx001) for the treatment of disseminated and high-risk adenovirus (AdV) infection</article-title>
  <source>Proceedings of the Bone Marrow Transplant Tandem Meetings</source>
  <conf-loc>San Diego, CA, USA</conf-loc>
  <conf-date>11â€“15 February 2015</conf-date>
 </element-citation>
</ref>
